ABEO - アビオナ・セラピュ―ティクス (Abeona Therapeutics Inc.) アビオナ・セラピュ―ティクス

 ABEOのチャート


 ABEOの企業情報

symbol ABEO
会社名 Abeona Therapeutics Inc (アビオナ・セラピュ―ティクス)
分野(sector) Health Care   ヘルスケア
産業(industry) Major Pharmaceuticals  
業種 バイオテクノロジ―_メディカルリサ―チ   医療関連(Health Care)
概要 事業概要 アベオナ・セラピューティクス(Abeona Therapeutics Inc.)は希少遺伝性疾患の新規遺伝子治療法を開発する臨床段階のバイオ医薬品会社である。同社の主導プログラムには、劣性栄養障害性表皮水疱症(RDEB)向けの遺伝子矯正皮膚移植片EB-101及びサンフィリッポ症候群A型(MPS IIIA)向けのアデノ随伴ウイルス(AAV)ベース遺伝子療法であるABO-102(AAV-SGSH)を含む。同社はまた、サンフリッポ症候群B型(MPS IIIB)向けのABO-101(AAV-NAGLU)、若年型バツテン疾患(JNCL)向けのABO-201(AAV-CLN3)、幼児型バツテン疾患(INCL)の治療向けのABO-202 (AAV-CLN1)、表皮水疱症向けのEB-201、ファンコーニ貧血障害向けのABO-301 (AAV-FANCC)、並びに希少血液疾患向けの遺伝子療法である新規クリスパー・キャス9(CRISPR/Cas9)ベースの遺伝子編集療法を使用するABO-302を開発する。同社はまた、独自のSalt Diafiltrationエタノールフリープロセスを使用して、遺伝性慢性閉塞性肺疾患(COPD)向けのアルファ-1プロテアーゼ阻害剤(SDF Alpha)を含む血漿ベースのタンパク質療法パイプラインを所有する。   アビオナ・セラピュ―ティクスは米国のバイオ医薬品メ―カ―。遺伝子治療や希少疾患のためのプラズマベ―スの製品の開発に焦点を当てる。主要プログラムとして、遺伝性ムコ多糖代謝異常のサンフィリポ症候群(MPS IIIA及びIIIB)を研究。同社の主な市販段階の製品には「MuGard」と「ProctiGard」がある。本社はテキサス州ダラス。   Abeona Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of gene therapy for severe and life threatening rare diseases. It programs include EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and ABO-101 (AAV NAGLU), an AAV based gene therapy for Sanfilippo syndrome type B (MPS IIIB). The company was founded in 1974 and is headquartered in New York, NY.
本社所在地 1330 Avenue of the Americas 33rd Floor New York NY 10019 USA
代表者氏名 Steven H. Rouhandeh スティーブンH.ローランハンド
代表者役職名 Executive Chairman of the Board 取締役会長
電話番号 +1 214-905-5100
設立年月日 27181
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 42人
url www.abeonatherapeutics.com
nasdaq_url https://www.nasdaq.com/symbol/abeo
adr_tso
EBITDA EBITDA(百万ドル) -33.99400
終値(lastsale) 11.13
時価総額(marketcap) 533608762.05
時価総額 時価総額(百万ドル) 516.34920
売上高 売上高(百万ドル) 3.85100
企業価値(EV) 企業価値(EV)(百万ドル) 396.50720
当期純利益 当期純利益(百万ドル) -33.95600
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Abeona Therapeutics Inc revenues increased from $403K to $3.4M. Net loss increased 49% to $20.2M. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Higher net loss reflects R&D exp increase from $1.8M to $14.1M (expense) Selling/General/Admin. Expense increase from $1.5M to $4.9M (expense).

 ABEOのテクニカル分析


 ABEOのニュース

   THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc. and Encourages Investors with Losses to Contact the Firm  2020/01/02 17:12:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $ABEO #ABEO--THURSDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abeona Therapeutics Inc.
   THURSDAY DEADLINE: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm  2019/12/31 17:30:00 Yahoo Finance
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian
   6-Day Deadline Alert: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm  2019/12/28 01:30:00 Yahoo Finance
Investors who purchased the Company's securities between May 31, 2018 and September 23, 2019, inclusive (the ''Class Period''), are encouraged to contact the firm before January 2, 2020. You can also reach us through the firm's website at www.schallfirm.com, or by email at brian
   DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors That a Class Action Lawsuit Has Been Filed Against Abeona Therapeutics, Inc. and Encourages Investors to Contact the Firm  2019/12/27 23:00:00 Business Wire
NEW YORK--(BUSINESS WIRE)-- #abeo--Bragar Eagel & Squire, P.C., a nationally recognized shareholder law firm, reminds investors that a class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of investors that purchased Abeona Therapeutics, Inc. (NASDAQ: ABEO) securities between May 31, 2018 and September 23, 2019 (the “Class Period”). Investors have until January 2, 2019 to apply to the Court to be appointed as lead plaintiff in the la
   FINAL DEADLINE APPROACHING: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abeona Therapeutics Inc. and Encourages Investors with Losses in Excess of $200,000 to Contact the Firm  2019/12/20 23:20:00 Yahoo Finance
LOS ANGELES, CA / ACCESSWIRE / December 20, 2019 / The Schall Law Firm ,a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abeona Therapeutics Inc. ("Abeona" …
   Regenxbio: A Stellar Gene Therapy Innovator With Multiple Upsides  2019-05-01
History has shown that in every age and in every field of human knowledge, many of the views which almost everyone accepted as true and never bothered to think about further, were in time proven completely wrong. - Phillip Fisher (Warren Buffett's Teacher) The largest profits are usually…

 関連キーワード  (バイオテクノロジ―_メディカルリサ―チ 米国株 アビオナ・セラピュ―ティクス ABEO Abeona Therapeutics Inc.)

 twitter  (公式ツイッターやCEOツイッターなど)